Voranigo® Recognized with Multiple Prix Galien Awards
Servier's Voranigo® (vorasidenib) has recently achieved remarkable recognition by winning the prestigious Prix Galien Awards in various regions. This acknowledgment serves as a testament to the significant strides made by Voranigo® in benefiting patients diagnosed with glioma. The awards include the Prix Galien USA, the Prix Galien Poland, and the Prix Galien Bridges Awards, all primarily focusing on Best Product for Orphan/Rare Diseases.
Acknowledgment for Innovative Advancements
The Prix Galien Awards highlight innovative advancements within the healthcare sector, specifically recognizing breakthrough products and exceptional research teams in pharmaceutical, biotech, medtech, and digital health arenas. With several awards under its belt, Voranigo® is paving the way for enhanced treatment options for glioma patients worldwide.
2025 Prix Galien Bridges Award
During a recent awards ceremony held in Stockholm, Voranigo® was honored with the inaugural 2025 Prix Galien Bridges Award for Best Product for Orphan/Rare Diseases. This award showcases the commitment that Servier has towards fostering life science innovation across multiple regions, including the Nordic countries and key biopharmaceutical communities from Europe and the Middle East.
Recognition in the USA and Poland
In addition to the Bridges Award, Voranigo® has also been bestowed with the highly esteemed Prix Galien USA Award and the Prix Galien Poland Award in the Best Product category for Orphan/Rare Diseases. These recognitions not only celebrate Servier's dedication to innovation but also validate the potential impact Voranigo® is set to have on patient care.
Commitment to Patients and Innovation
Arnaud Lallouette, Executive Vice-President of Global Medical & Patient Affairs at Servier, expressed gratitude for these accolades, emphasizing their significance in recognizing the scientific advancements Voranigo® brings to glioma patients. Lallouette stated, "We are truly honored to receive these prestigious distinctions in several countries. It recognizes the scientific progress that Voranigo® can bring to patients living with glioma across the world. It rewards Servier's commitment to innovation and to patients as we continue to advance precision oncology for all who stand to benefit."
Clinical Significance of Voranigo®
Voranigo® has received marketing authorization to treat predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma cases associated with specific mutations in adults and adolescents aged 12 years and older. Particularly, it targets individuals diagnosed with an isocitrate dehydrogenase-1 (IDH1) R132 or isocitrate dehydrogenase-2 (IDH2) R172 mutation, provided they weigh at least 40 kg and are not requiring immediate radiotherapy or chemotherapy after surgical interventions.
About Servier
Servier is recognized as an independent international pharmaceutical company dedicated to delivering innovative treatment solutions. As they continue to make strides in oncology and various other therapeutic areas, they remain committed to fostering a healthier future for patients globally. As part of their outreach, Servier encourages following their developments and updates through their official social media platforms.
Frequently Asked Questions
What is Voranigo® and what condition does it treat?
Voranigo® (vorasidenib) is an innovative treatment primarily used for adults and adolescents with specific genetic mutations associated with low-grade gliomas.
Which awards has Voranigo® recently received?
Voranigo® has won the Prix Galien USA, Prix Galien Poland, and the Prix Galien Bridges Awards for its exceptional performance in treating orphan/rare diseases.
What does the Prix Galien Award signify?
The Prix Galien Award is a prestigious accolade that honors significant innovations in the life sciences field, recognizing breakthrough products and outstanding research teams.
Who is Servier?
Servier is an independent international pharmaceutical group committed to providing innovative healthcare solutions and improving patient outcomes through advanced medical research.
What is the significance of the Prix Galien Bridges Award?
The Prix Galien Bridges Award highlights the innovation in life sciences, especially recognizing contributions within the Nordic countries and their connection to key biopharmaceutical sectors in Europe and the Middle East.